Summary of GE HealthCare Technologies FY Conference Call Company Overview - **Company**: GE HealthCare Technologies (NasdaqGS:GEHC) - **Date of Conference**: March 10, 2026 Key Industry Insights - **Middle East Exposure**: - GE HealthCare's exposure to the Middle East is less than 5% of its overall business, indicating limited risk from regional disruptions [5][7] - The company is focused on ensuring safety and continuity of operations amidst regional conflicts [3][4] - **Oil Price Impact**: - The company is monitoring the implications of rising oil prices but has multiple levers to offset potential impacts, including pricing strategies and productivity initiatives [12][13] - Logistics costs are more affected by oil prices than the cost of goods sold, as the company does not have a significant resin component in its products [15] - **Tariff Management**: - Tariff expenses were approximately $250 million last year and are expected to decrease this year [18] - The company successfully mitigated initial tariff impacts from $1 billion to $250 million through strategic supply chain management [19] - Recent tariff changes, including the replacement of IEEPA tariffs with Section 122 tariffs, are expected to have similar financial impacts [20][21] Product and Innovation Highlights - **Product Launches**: - GE HealthCare has launched several innovative products, including: - **Vivid Pioneer**: A cardiovascular ultrasound device that reduces echocardiograph time and enhances image quality [34] - **Allia Moveo**: A next-generation X-ray machine for interventional procedures [35] - **LOGIQ R5**: A general ultrasound imaging device that significantly reduces scan time and clicks [36] - **Future Product Expectations**: - Anticipated launches of **total body PET** and **photon-counting CT** are expected to drive significant revenue growth, primarily in 2027 [40][41] - The company has a record backlog of $2 billion year-over-year, supporting its growth forecast of 3%-4% for the current year [32] Competitive Landscape - **Generic Competition**: - Amneal's entry into the market with a generic version of GE HealthCare's iohexol product is acknowledged, but the company remains confident in its market position due to consistency of supply, product quality, and brand recognition [28][29] Financial Outlook - **Growth Projections**: - The company expects a growth rate of 3%-4% driven by commercial initiatives and a strong product pipeline, with a focus on maintaining a resilient supply chain [30][32] - The impact of new product innovations is expected to be more pronounced in 2027, with some contributions anticipated in the latter half of 2026 [41][42] Conclusion - GE HealthCare Technologies is navigating current geopolitical and economic challenges while focusing on innovation and strategic supply chain management to sustain growth and mitigate risks. The company is well-positioned to leverage its product pipeline and market leadership in the medical devices sector.

Core Viewpoint - GE Healthcare's CEO emphasizes China's role as a significant contributor to the global economy and the importance of its open cooperation for multinational companies [3][7]. Investment and Market Presence - GE Healthcare has established six production bases in China, employing approximately 7,000 people and expanding its local R&D team to 1,800, which has launched over 160 locally innovative products since 2011 [4]. - The company has committed to a five-year investment plan of 500 million yuan in its Tianjin base, with a new R&D center expected to open by the end of 2025 [5]. Innovation and Collaboration - The innovation centers in China are part of GE Healthcare's strategy to leverage local resources and expertise, particularly in software engineering, AI, and robotics [6]. - The company is focused on localizing its operations by designing and manufacturing products in China, which includes developing specific medical devices for the Chinese market [8]. Long-term Commitment - GE Healthcare's long-term commitment to the Chinese market is unwavering, as the company believes success in China is crucial for its global success [7]. - The CEO highlights the resilience of the Chinese market and the increasing demand for quality healthcare services, especially in western provinces [7].

Investment Rating - Industry investment rating: Outperform the market (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [1][44] Core Viewpoints - The overall procurement scale in 2024 is expected to be 137.1 billion yuan, a year-on-year decrease of 20%, primarily due to the pace of equipment updates at the beginning of 2024. However, a significant improvement is anticipated in Q4 2024 and Q1 2025 due to rapid implementation of equipment updates and accelerated budget usage by hospitals [3][11] - High-end imaging equipment is experiencing a notable recovery in bidding activities, with significant year-on-year growth rates observed in CT and MRI equipment procurement in late 2024 and early 2025 [5][19] - The domestic equipment localization rate is steadily increasing, driven by intensified price competition and supportive policies for domestic medical devices. Leading domestic companies are gaining market share in key equipment categories [6][31] Summary by Sections Procurement Scale and Trends - The procurement scale for medical devices in 2024 is projected to be 137.1 billion yuan, down 20% year-on-year, with a recovery expected in Q4 2024 due to equipment updates and budget utilization [3][11] - In December 2024, procurement reached 25.3 billion yuan, a 49% increase year-on-year, and in January 2025, it reached 16.9 billion yuan, a 40% increase year-on-year [3][11] High-end Imaging Equipment - High-end imaging equipment, particularly CT and MRI, is seeing a resurgence in procurement, with December 2024 CT procurement growing by 70% year-on-year and MRI by 55% [5][19] - PET equipment also shows significant growth, with December 2024 procurement increasing by 200% year-on-year and January 2025 by 546% [5][19] Localization Rate - The localization rate for major medical equipment is expected to improve in 2024, supported by competitive pricing and government policies favoring domestic products [6][30] - Leading domestic companies such as Mindray, United Imaging, and others are expected to increase their market share in key segments like CT, MRI, and PET equipment [31][30] Investment Recommendations - Looking ahead to 2025, the ongoing equipment update policies are expected to positively impact industry bidding growth. Key companies in high-end and intelligent medical equipment should be closely monitored [40][41]